Blood microRNA-15a Correlates with IL-6, IGF-1 and Acute Cerebral Ischemia

Area of Science:

• Biochemistry
• Molecular Biology
• Neuroscience

Background:

• Acute cerebral ischemia (AIS) poses a significant health challenge, necessitating novel diagnostic and therapeutic strategies.
• MicroRNAs (miRNAs) are emerging as critical regulators in various biological processes, including those involved in ischemic stroke pathogenesis.
• Understanding the role of specific miRNAs, such as microRNA-15a (miR-15a), in AIS is crucial for developing targeted interventions.

Purpose of the Study:

• To investigate the role and clinical significance of blood miR-15a in the pathogenesis of acute cerebral ischemia (AIS).
• To evaluate miR-15a as a potential diagnostic biomarker for stroke.
• To explore the relationship between miR-15a levels and stroke severity, etiology, and prognosis.

Main Methods:

• Blood samples were collected from AIS patients and healthy controls.
• A human umbilical vein endothelial cell (HUVEC) model of ischemia was established using oxygen-glucose deprivation (OGD).
• Real-time quantitative PCR (qPCR) was used to measure miR-15a levels; ELISA measured IL-6 and IGF-1. Statistical analysis was performed using SPSS.

Main Results:

• Elevated miR-15a levels were observed in AIS patients and ischemic cells compared to controls (p < 0.05).
• Blood miR-15a demonstrated high specificity (98.67%) in predicting stroke onset and negatively correlated with NIHSS scores (r = -0.3695, p < 0.01).
• Higher miR-15a levels were associated with a better prognosis and specific stroke types (anterior circulation infarction, small-artery atherosclerosis); plasma IL-6 and IGF-1 levels showed significant correlations with miR-15a.

Conclusions:

• Blood miR-15a is associated with acute cerebral ischemia, IL-6, and IGF-1.
• miR-15a levels correlate with stroke severity and prognosis.
• Blood miR-15a holds potential as a diagnostic biomarker and therapeutic target for stroke.